ASTRAZENECA PLC

AZN
Real-time Estimate Quote. Real-time Estimate  - 06/18 11:30:00 am
8353GBX -0.36%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Number of employees : 76 100 people.
Sales per Business
20192020
GBP
(in Million)
%GBP
(in Million)
%
Oncology 6,79435.5% 8,46139.3%
Cardiovascular, Renal & Metabolism 5,41328.3% 5,53425.7%
Respiratory 4,22622.1% 4,17719.4%
Other Diseases 2,03910.7% 2,0179.4%
Externalisation Revenue 641.983.4% 566.932.6%
Sales per region
2020
GBP
(in Million)
%
United States 6,98332.5%
China 4,16819.4%
Japan 2,0029.3%
United Kingdom 1,3586.3%
Other Asia, Africa and Australasia 1,1965.6%
Other Continental Europe 1,0855%
Sweden 800.093.7%
Germany 730.693.4%
Other Americas 593.442.8%
France 509.222.4%
Managers
Name Title
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Henry D. Cremisi Medical Director
Hasan Jafri Senior Medical Director
Katarina Ageborg Chief Compliance Officer & EVP-Sustainability
Marcus Wallenberg Independent Non-Executive Director
Philip Arthur John Broadley Senior Independent Non-Executive Director
Shareholders
Name Equities %
Wellington Management Co. LLP 68,525,329 5.22%
Capital Research & Management Co. (World Investors) 56,102,804 4.27%
BlackRock Investment Management (UK) Ltd. 54,582,684 4.16%
Investor AB (Investment Company) 51,587,810 3.93%
The Vanguard Group, Inc. 35,249,067 2.69%
Norges Bank Investment Management 30,235,000 2.30%
BlackRock Fund Advisors 24,893,988 1.90%
BlackRock Advisors (UK) Ltd. 17,042,861 1.30%
SSgA Funds Management, Inc. 13,584,656 1.03%
State Street Global Advisors Ltd. 12,014,420 0.92%
Company contact information
AstraZeneca Plc
Cambridge Biomedical Campus
1 Francis Crick Avenue
Cambridge, Cambridgeshire CB2 0AA

Phone : +44.20.3749.5000
Fax : +44.12.2335.2858
Web : http://www.astrazeneca.com
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
ASTRAZENECA PLC16.72%153 347
JOHNSON & JOHNSON4.98%435 090
ROCHE HOLDING AG12.75%328 768
PFIZER, INC.7.25%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.7.23%202 939
ELI LILLY AND COMPANY31.61%201 995
MERCK & CO., INC.-5.59%195 551
NOVO NORDISK A/S20.68%189 536
ASTRAZENECA PLC14.46%153 347
BRISTOL-MYERS SQUIBB COMPANY7.64%149 087
AMGEN INC.4.71%138 330
SANOFI12.95%132 466
GLAXOSMITHKLINE PLC6.96%100 085
JIANGSU HENGRUI MEDICINE CO., LTD.-23.40%70 289
CHUGAI PHARMACEUTICAL CO., LTD.-21.02%64 764
ALLERGAN PLC0.97%63 659
BAYER AG11.04%62 588
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.05%53 301
DAIICHI SANKYO COMPANY, LIMITED-27.74%44 370
ASTELLAS PHARMA INC.21.68%32 656
Brand Portfolio
ACERTA PHARMA
ACERTA PHARMA
ALMIRALL
ALMIRALL
ARDEA BIOSCIENCES
ARDEA BIOSCIENCES
ASTRAZENECA
ASTRAZENECA
ZS PHARMA
ZS PHARMA
» More brands of AstraZeneca PLC